Objective To explore the effects of hyperbaric oxygen ( HBO) combined with memantine hydrochloride in the treatment of Alzheimer's disease and its impact on the levels of serum SOD and NSE. Methods Eighty-eight patients with Alzheimer's disease admitted to our hospital from June 2015 to June 2018 were selected as the study subjects. The patients were divided into the combined group and the control group, in accordance with different treatment methods. The control group was treated with memantine hydrochloride, while the combined group was treated with HBO coupled with memantine hydrochloride. After 8 weeks of treatment, the clinical effects were compared between the patients of the 2 groups. Mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) were used to assess the cognitive status of the patients. The changes of serum SOD and NSE levels were compared and adverse reactions of the 2 groups were analyzed for the patients of the 2 groups. Results The total effective rate of the combined group (84. 09％)was obviously higher than that of the control group (63. 64％) (χ2 = 4. 768, P=0. 029). After treatment, the scores of MMSE and MoCA in the combined group were (21. 42 ± 1. 15) and (25. 46 ± 1. 39) respectively, while those in the control group were (18. 37 ± 1. 05) and (22. 31 ± 1. 22) respectively (all P<0. 05). Following treatment, the serum SOD levels of the 2 groups all increased, and the serum NSE level decreased (P<0. 05). No significant significance could be noticed in the rate of adverse reactions, when comparisons were made between the 2 groups (χ2 =0. 067, P=0. 769). Conclusion HBO combined with memantine hydrochloride in the treatment of Alzheimer's disease has good clinical efficacy, and could significantly improve the cognitive function of the patients, and increase serum SOD level, reduce NSE level and alleviate oxidative stress injury in the patients.

Objective To explore the effects of hyperbaric oxygen ( HBO) combined with memantine hydrochloride in the treatment of Alzheimer's disease and its impact on the levels of serum SOD and NSE. Methods Eighty-eight patients with Alzheimer's disease admitted to our hospital from June 2015 to June 2018 were selected as the study subjects. The patients were divided into the combined group and the control group, in accordance with different treatment methods. The control group was treated with memantine hydrochloride, while the combined group was treated with HBO coupled with memantine hydrochloride. After 8 weeks of treatment, the clinical effects were compared between the patients of the 2 groups. Mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) were used to assess the cognitive status of the patients. The changes of serum SOD and NSE levels were compared and adverse reactions of the 2 groups were analyzed for the patients of the 2 groups. Results The total effective rate of the combined group (84. 09％)was obviously higher than that of the control group (63. 64％) (χ2 = 4. 768, P=0. 029). After treatment, the scores of MMSE and MoCA in the combined group were (21. 42 ± 1. 15) and (25. 46 ± 1. 39) respectively, while those in the control group were (18. 37 ± 1. 05) and (22. 31 ± 1. 22) respectively (all P<0. 05). Following treatment, the serum SOD levels of the 2 groups all increased, and the serum NSE level decreased (P<0. 05). No significant significance could be noticed in the rate of adverse reactions, when comparisons were made between the 2 groups (χ2 =0. 067, P=0. 769). Conclusion HBO combined with memantine hydrochloride in the treatment of Alzheimer's disease has good clinical efficacy, and could significantly improve the cognitive function of the patients, and increase serum SOD level, reduce NSE level and alleviate oxidative stress injury in the patients.